Repligen Balance Sheet Health
Financial Health criteria checks 4/6
Repligen has a total shareholder equity of $2.0B and total debt of $579.6M, which brings its debt-to-equity ratio to 29.4%. Its total assets and total liabilities are $2.8B and $853.2M respectively. Repligen's EBIT is $25.7M making its interest coverage ratio -2. It has cash and short-term investments of $751.3M.
Key information
29.4%
Debt to equity ratio
US$579.60m
Debt
| Interest coverage ratio | -2x |
| Cash | US$751.32m |
| Equity | US$1.97b |
| Total liabilities | US$853.21m |
| Total assets | US$2.82b |
Recent financial health updates
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Recent updates
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Apr 30Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet
Apr 15At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?
Feb 13Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Jan 08Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price
Dec 19What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?
Nov 01Is Repligen (NASDAQ:RGEN) Using Too Much Debt?
Oct 17Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?
Sep 29Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade
Aug 09Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?
Jul 17Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?
Jul 03With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case
Jun 19Calculating The Fair Value Of Repligen Corporation (NASDAQ:RGEN)
May 23Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Apr 11Is Now An Opportune Moment To Examine Repligen Corporation (NASDAQ:RGEN)?
Mar 28We Ran A Stock Scan For Earnings Growth And Repligen (NASDAQ:RGEN) Passed With Ease
Mar 08Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Feb 20Repligen (NASDAQ:RGEN) Seems To Use Debt Quite Sensibly
Jan 10Should You Think About Buying Repligen Corporation (NASDAQ:RGEN) Now?
Dec 28Is Repligen (NASDAQ:RGEN) A Risky Investment?
Oct 03Repligen: Now Best Biotech Nearby Cap-Gain Prospect
Sep 27Repligen partners with DRS daylight solutions
Sep 19When Should You Buy Repligen Corporation (NASDAQ:RGEN)?
Sep 19Do Repligen's (NASDAQ:RGEN) Earnings Warrant Your Attention?
Aug 23Repligen briefly turns positive after report of rejected takeover offer
Aug 11Calculating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)
Aug 08Financial Position Analysis
Short Term Liabilities: RGEN's short term assets ($1.1B) exceed its short term liabilities ($158.2M).
Long Term Liabilities: RGEN's short term assets ($1.1B) exceed its long term liabilities ($695.0M).
Debt to Equity History and Analysis
Debt Level: RGEN has more cash than its total debt.
Reducing Debt: RGEN's debt to equity ratio has increased from 16.8% to 29.4% over the past 5 years.
Debt Coverage: RGEN's debt is not well covered by operating cash flow (19.7%).
Interest Coverage: RGEN earns more interest than it pays, so coverage of interest payments is not a concern.